India, Dec. 2 -- Biomoneta, a Bengaluru-based healthtech company building advanced air-decontamination technologies, has announced that its flagship product Avata Rx, powered by its proprietary ZeBox(R) microbicidal technology, has received approval from the United States Food and Drug Administration (US FDA), marking the first time an Indian company has achieved FDA clearance in the air-decontamination category.

Biomoneta enters the global arena at a time when the clean-air and infection-prevention sector is undergoing rapid transformation, with a combined global TAM spanning Healthcare Facilities ($15-20 billion), Consumer/Residential Air Purifiers ($17-20 billion), Commercial & Industrial HVAC Clean-Air systems ($50-60 billion), HVAC ...